1
|
Laufer NL, Bouzas MB, Fernández Giuliano S, Zapiola I, Mammana L, Salomon H, Monzani C, Castro G, Suarez Ornani ML, Rojas Machado P, Cochon N, Adazsko A, Ravasi G, Vila M, Maulen S, Ceriotto M, Barbas MG, Martini S. Pretreatment HIV-1 Resistance in Argentina: Results from the Second Surveillance Study Following World Health Organization Guidelines (2019). AIDS Res Hum Retroviruses 2024. [PMID: 38386507 DOI: 10.1089/aid.2023.0083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2024] Open
Abstract
More than 62,000 individuals are currently on antiretroviral treatment within the public health system in Argentina. In 2019, more than 50% of people on ART received non-nucleoside reverse transcriptase inhibitors (NNRTIs). In this context, the second nationwide HIV-1 pretreatment drug resistance surveillance study was carried out between April and December 2019 to assess the prevalence of HIV-1 drug resistance in Argentina using the World Health Organization guidelines. This was a nationwide cross-sectional study enrolling consecutive 18-year-old and older individuals starting ARVs at 19 ART-dispensing centers. This allowed us to estimate a point prevalence rate of resistance-associated mutations (RAMs) with a confidence interval (CI) of 5% (for the total population and for those without antiretroviral exposure). Four-hundred forty-seven individuals were included in the study. The prevalence of mutations associated with resistance was detected in 27.7% (95% CI 25.6-34.9%) of the population. For NNRTI, it was 19.6% (95% CI 16.3-24.5%), for integrase strand transfer inhibitor (INSTI) 6.1% (95% CI 6.1-11.9%), for nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) 3% (95% CI 1.9-5.9%), and for protease inhibitors 1.5% (95% CI 0.7-3.6%). Naive individuals had variants of resistance to NRTIs in 16.8% (95% CI 12.8-21.4) and 5.7% (95% CI 2.9-15.9) to INSTI. For experienced individuals, the prevalence of variants associated with resistance was 30.38% (95% CI 20.8-42.2) for NRTIs and 7.7% (95% CI 2.9-15.9) for INSTI. This study shows an increase in the frequency of nonpolymorphic RAMs associated with resistance to NNRTI. This study generates the framework of evidence that supports the use of schemes based on high genetic barrier integrase inhibitors as the first line of treatment and the need for the use of resistance test before prescribing schemes based on NNRTI. We report for the first time the presence of a natural polymorphism associated with the most prevalent recombinant viral form in Argentina and the presence of a mutation linked to first-line integrase inhibitors such as raltegravir.
Collapse
Affiliation(s)
- Natalia L Laufer
- Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | | | | | - Ines Zapiola
- Hospital Muñiz, Ciudad de Buenos Aires, Argentina
| | | | - Horacio Salomon
- Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Cecilia Monzani
- Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Gonzalo Castro
- Laboratorio Central de Córdoba, Ciudad de Córdoba, Argentina
| | - Maria Laura Suarez Ornani
- Dirección de Respuesta al VIH, ITS, Hepatitis Virales y Tuberculosis, Ministerio de Salud de la Nación, Ciudad de Buenos Aires, Argentina
| | - Paula Rojas Machado
- Dirección de Respuesta al VIH, ITS, Hepatitis Virales y Tuberculosis, Ministerio de Salud de la Nación, Ciudad de Buenos Aires, Argentina
| | - Natalia Cochon
- Dirección de Respuesta al VIH, ITS, Hepatitis Virales y Tuberculosis, Ministerio de Salud de la Nación, Ciudad de Buenos Aires, Argentina
| | - Ariel Adazsko
- Dirección de Respuesta al VIH, ITS, Hepatitis Virales y Tuberculosis, Ministerio de Salud de la Nación, Ciudad de Buenos Aires, Argentina
| | - Giovanni Ravasi
- Pan American Health Organization, Washington, District of Columbia, USA
| | - Marcelo Vila
- Pan American Health Organization, Ciudad de Buenos Aires, Argentina
| | - Sergio Maulen
- Dirección de Respuesta al VIH, ITS, Hepatitis Virales y Tuberculosis, Ministerio de Salud de la Nación, Ciudad de Buenos Aires, Argentina
| | - Mariana Ceriotto
- Dirección de Respuesta al VIH, ITS, Hepatitis Virales y Tuberculosis, Ministerio de Salud de la Nación, Ciudad de Buenos Aires, Argentina
| | | | - Sergio Martini
- Dirección de Respuesta al VIH, ITS, Hepatitis Virales y Tuberculosis, Ministerio de Salud de la Nación, Ciudad de Buenos Aires, Argentina
| |
Collapse
|
2
|
Hoxha A, Kerr SM, Laurenson-Schafer H, Sklenovská N, Mirembe BB, Nezu IH, Ndumbi P, Fitzner J, Almiron M, Vila M, Pebody R, Vaughan AM, Haussig JM, de Sousa LA, Lukoya OC, Sanni OF, Nabeth P, Naiene JD, Kato M, Matsui T, Kuppalli K, Mala PO, Lewis RF, de Waroux OLP, Pavlin BI. Mpox in Children and Adolescents during Multicountry Outbreak, 2022-2023. Emerg Infect Dis 2023; 29:2125-2129. [PMID: 37647121 PMCID: PMC10521596 DOI: 10.3201/eid2910.230516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023] Open
Abstract
The 2022-2023 mpox outbreak predominantly affected adult men; 1.3% of reported cases were in children and adolescents <18 years of age. Analysis of global surveillance data showed 1 hospital intensive care unit admission and 0 deaths in that age group. Transmission routes and clinical manifestations varied across age subgroups.
Collapse
Affiliation(s)
| | | | - Henry Laurenson-Schafer
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Nikola Sklenovská
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Bernadette Basuta Mirembe
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Ingrid Hammermeister Nezu
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Patricia Ndumbi
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Julia Fitzner
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Maria Almiron
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Marcelo Vila
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Richard Pebody
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Aisling M. Vaughan
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Joana M. Haussig
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Luis Alves de Sousa
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Okot Charles Lukoya
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Olaniyi Felix Sanni
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Pierre Nabeth
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Jeremias Domingos Naiene
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Masaya Kato
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Tamano Matsui
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Krutika Kuppalli
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Peter Omondi Mala
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Rosamund F. Lewis
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Olivier le Polain de Waroux
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - Boris I. Pavlin
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| | - WHO Mpox surveillance and Analytics Team
- Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin)
- CPC Analytics, Berlin, Germany (S.M. Kerr)
- WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila)
- WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan)
- European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa)
- WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni)
- WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene)
- WHO Regional Office for South-East Asia, Delhi, India (M. Kato)
- WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)
| |
Collapse
|
3
|
Ciscar A, Ruiz P, Saez E, Vila M, Gomez M, Troyano D, Abadal M, Pereira JA, Badia JM. OC-069 EFECTIVENESS OF PROPHYLACTIC ONLAY MESH FOR PREVENTION OF TROCAR HERNIA: PRELIMINARY RESULTS OF A RANDOMIZED CLINICAL TRIAL. Br J Surg 2022. [DOI: 10.1093/bjs/znac308.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Aim
Trocar site hernia (TSH) incidence is a common complication of laparoscopic surgery. In the literature there is a lack of tools to prevent it. Our aim was to assess the effectiveness and safety of a prophylactic measure to decrease it.
Methods
A multicentric randomized clinical trial was performed in high-risk patients (diabetes mellitus and/or age ≥70 years and/or BMI ≥30 Kg/m2 and/or extended incision for specimen retrieval) who underwent laparoscopic cholecystectomy in an elective or emergency setting. Patients were allocated to prophylactic onlay polypropylene mesh fixation (intervention) or standard trocar closure (control). The main aim was to analyze the efficacy of the intervention, being TSH incidence the primary outcome. Clinical and radiological follow up was atleast 1 year after surgery. Secondary endpoints were technique-related complications.
Results
134 patients were included (70 and 62 to intervention and control arm, respectively). Groups were homogeneous. Mean [SD] age, 64.8 (17.3) years; 80 (60, 6%) women. The cumulative TSH incidence was lower in the intervention group although not reaching significant differences, either when were radiologically (16 [26.7%] vs 17 [37%], p = 0.294) or clinically assessed (9 [17.6%] vs 9 [24.3], p = 0.593). No differences in surgical site infection, hematoma or seroma were detected. Mean follow-up was 736 days (min. 365 – max. 1294).
Conclusions
Our preliminary results points out that the overall TSH incidence is extremely high when properly assessed. A polypropylene onlay mesh would not be an effective measure to decrease the TSH incidence. Radiological evaluation would show more accuracy.
Collapse
Affiliation(s)
- A Ciscar
- General Surgery, Hospital de Mataró - Consorci Sanitari del Maresme , Mataró , Spain
| | - P Ruiz
- General Surgery, Hospital de Granollers , Granollers , Spain
| | - E Saez
- General Surgery, Hospital de Sant Boi , Sant Boi de Llobregat , Spain
| | - M Vila
- General Surgery, Hospital de Mataró - Consorci Sanitari del Maresme , Mataró , Spain
| | - M Gomez
- General Surgery, Hospital de Calella , Calella , Spain
| | - D Troyano
- General Surgery, Hospital Esperit Sant , Santa Coloma de Gramenet , Spain
| | - M Abadal
- General Surgery, Hospital de Mataró - Consorci Sanitari del Maresme , Mataró , Spain
| | - J A Pereira
- General Surgery, Hospital Universitari del Mar , Barcelona , Spain
| | - J M Badia
- General Surgery, Hospital de Granollers , Granollers , Spain
| |
Collapse
|
4
|
Ravi Y, Raines T, Copeland L, Zaver S, Zaver H, Vila M, Pacific M, Sai-Sudhakar C, Calderia C. Independent and Combined Effects of Age and COVID on Patient Outcomes. J Heart Lung Transplant 2022. [PMCID: PMC8988568 DOI: 10.1016/j.healun.2022.01.666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
5
|
Osorio J, Madrazo Z, Videla S, Sainz B, Rodríguez-González A, Campos A, Santamaría M, Pelegrina A, González-Serrano C, Aldeano A, Sarriugarte A, Gómez-Díaz CJ, Ruiz-Luna D, García-Ruiz-de-Gordejuela A, Gómez-Gavara C, Gil-Barrionuevo M, Vila M, Clavell A, Campillo B, Millán L, Olona C, Sánchez-Cordero S, Medrano R, López-Arévalo CA, Pérez-Romero N, Artigau E, Calle M, Echenagusia V, Otero A, Tebe C, Pallares N, Biondo S. Analysis of outcomes of emergency general and gastrointestinal surgery during the COVID-19 pandemic. Br J Surg 2021; 108:1438-1447. [PMID: 34535796 DOI: 10.1093/bjs/znab299] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 07/25/2021] [Indexed: 11/12/2022]
Abstract
BACKGROUND Few surgical studies have provided adjusted comparative postoperative outcome data among contemporary patients with and without COVID-19 infection and patients treated before the pandemic. The aim of this study was to determine the impact of performing emergency surgery in patients with concomitant COVID-19 infection. METHODS Patients who underwent emergency general and gastrointestinal surgery from March to June 2020, and from March to June 2019 in 25 Spanish hospitals were included in a retrospective study (COVID-CIR). The main outcome was 30-day mortality. Secondary outcomes included postoperative complications and failure to rescue (mortality among patients who developed complications). Propensity score-matched comparisons were performed between patients who were positive and those who were negative for COVID-19; and between COVID-19-negative cohorts before and during the pandemic. RESULTS Some 5307 patients were included in the study (183 COVID-19-positive and 2132 COVID-19-negative during pandemic; 2992 treated before pandemic). During the pandemic, patients with COVID-19 infection had greater 30-day mortality than those without (12.6 versus 4.6 per cent), but this difference was not statistically significant after propensity score matching (odds ratio (OR) 1.58, 95 per cent c.i. 0.88 to 2.74). Those positive for COVID-19 had more complications (41.5 versus 23.9 per cent; OR 1.61, 1.11 to 2.33) and a higher likelihood of failure to rescue (30.3 versus 19.3 per cent; OR 1.10, 0.57 to 2.12). Patients who were negative for COVID-19 during the pandemic had similar rates of 30-day mortality (4.6 versus 3.2 per cent; OR 1.35, 0.98 to 1.86) and complications (23.9 versus 25.2 per cent; OR 0.89, 0.77 to 1.02), but a greater likelihood of failure to rescue (19.3 versus 12.9 per cent; OR 1.56, 95 per cent 1.10 to 2.19) than prepandemic controls. CONCLUSION Patients with COVID-19 infection undergoing emergency general and gastrointestinal surgery had worse postoperative outcomes than contemporary patients without COVID-19. COVID-19-negative patients operated on during the COVID-19 pandemic had a likelihood of greater failure-to-rescue than prepandemic controls.
Collapse
Affiliation(s)
- J Osorio
- Department of Surgery, Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain
| | - Z Madrazo
- Department of Surgery, Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain
| | - S Videla
- Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital/Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - B Sainz
- Department of Surgery, Complejo Hospitalario de Navarra, Pamplona, Spain
| | | | - A Campos
- Department of Surgery, Parc Taulí Health Corporation, Sabadell Hospital, Sabadell, Spain
| | - M Santamaría
- Department of Surgery, Arnau de Vilanova University Hospital, Lleida, Spain
| | - A Pelegrina
- Department of Surgery, Hospital del Mar University Hospital, Barcelona, Spain
| | | | - A Aldeano
- Department of Surgery, Granollers General Hospital, Granollers, Spain
| | - A Sarriugarte
- Department of Surgery, Cruces University Hospital, Bilbao, Spain
| | - C J Gómez-Díaz
- Department of Surgery, Althaia Foundation, Manresa, Spain
| | - D Ruiz-Luna
- Department of Surgery, Terrassa Health Consortium, Terrassa Hospital, Terrassa, Spain
| | | | - C Gómez-Gavara
- Hepatobiliopancreatic Surgery and Transplantation Department, Vall d'Hebrón University Hospital, Barcelona, Spain
| | | | - M Vila
- Department of Surgery, Mataró Hospital, Maresme Health Consortium, Mataró, Spain
| | - A Clavell
- Department of Surgery, Germans Trias i Pujol University Hospital, Badalona, Spain
| | - B Campillo
- Department of Surgery, Sant Joan de Deu Hospital Foundation, Martorell, Spain
| | - L Millán
- Department of Surgery, Dr José Molina Orosa Hospital, Lanzarote, Spain
| | - C Olona
- Department of Surgery, Joan XXIII University Hospital, Tarragona, Spain
| | - S Sánchez-Cordero
- Department of Surgery, Igualada University Hospital, Anoia Health Consortium, Igualada, Spain
| | - R Medrano
- Department of Surgery, Sant Pau University Hospital, Barcelona, Spain
| | - C A López-Arévalo
- Department of Surgery, Moisès Broggi Hospital, Sant Joan Despí, Spain
| | - N Pérez-Romero
- Department of Surgery, Mútua de Terrassa University Hospital, Terrassa, Spain
| | - E Artigau
- Department of Surgery, Girona Dr Josep Trueta University Hospital, Girona, Spain
| | - M Calle
- Department of Surgery, Alto Deba Hospital, Mondragon, San Sebastián, Spain
| | - V Echenagusia
- Department of Surgery, Araba University Hospital, Txagorritxu Hospital, Vitoria, Spain
| | - A Otero
- Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital/Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Tebe
- Statistical Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - N Pallares
- Statistical Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - S Biondo
- Department of Surgery, Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain
| | | |
Collapse
|
6
|
Bourdenx M, Nioche A, Dovero S, Arotcarena ML, Camus S, Porras G, Thiolat ML, Rougier NP, Prigent A, Aubert P, Bohic S, Sandt C, Laferrière F, Doudnikoff E, Kruse N, Mollenhauer B, Novello S, Morari M, Leste-Lasserre T, Trigo-Damas I, Goillandeau M, Perier C, Estrada C, Garcia-Carrillo N, Recasens A, Vaikath NN, El-Agnaf OMA, Herrero MT, Derkinderen P, Vila M, Obeso JA, Dehay B, Bezard E. Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates. Sci Adv 2020; 6:eaaz9165. [PMID: 32426502 PMCID: PMC7220339 DOI: 10.1126/sciadv.aaz9165] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Accepted: 03/06/2020] [Indexed: 06/11/2023]
Abstract
Dopaminergic neuronal cell death, associated with intracellular α-synuclein (α-syn)-rich protein aggregates [termed "Lewy bodies" (LBs)], is a well-established characteristic of Parkinson's disease (PD). Much evidence, accumulated from multiple experimental models, has suggested that α-syn plays a role in PD pathogenesis, not only as a trigger of pathology but also as a mediator of disease progression through pathological spreading. Here, we have used a machine learning-based approach to identify unique signatures of neurodegeneration in monkeys induced by distinct α-syn pathogenic structures derived from patients with PD. Unexpectedly, our results show that, in nonhuman primates, a small amount of singular α-syn aggregates is as toxic as larger amyloid fibrils present in the LBs, thus reinforcing the need for preclinical research in this species. Furthermore, our results provide evidence supporting the true multifactorial nature of PD, as multiple causes can induce a similar outcome regarding dopaminergic neurodegeneration.
Collapse
Affiliation(s)
- M. Bourdenx
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - A. Nioche
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- Institut Jean Nicod, Département d’études cognitives, ENS, EHESS, PSL Research University, 75005 Paris, France
- Institut Jean Nicod, Département d’études cognitives, CNRS, UMR 8129, Paris, France
| | - S. Dovero
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - M.-L. Arotcarena
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - S. Camus
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - G. Porras
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - M.-L. Thiolat
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - N. P. Rougier
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- INRIA Bordeaux Sud-Ouest, 33405 Talence, France
| | - A. Prigent
- INSERM, U1235, Nantes F-44035, France
- Nantes University, Nantes F-44035, France
- CHU Nantes, Department of Neurology, Nantes F-44093, France
| | - P. Aubert
- INSERM, U1235, Nantes F-44035, France
- Nantes University, Nantes F-44035, France
- CHU Nantes, Department of Neurology, Nantes F-44093, France
| | - S. Bohic
- EA-7442 Rayonnement Synchrotron et Recherche Medicale, RSRM, University of Grenoble Alpes, 38000 Grenoble, France
| | - C. Sandt
- SMIS beamline, Synchrotron SOLEIL, l’orme des merisiers, 91192 Gif sur Yvette, France
| | - F. Laferrière
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - E. Doudnikoff
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - N. Kruse
- Paracelsus-Elena-Klinik, Kassel, Germany
- University Medical Center Goettingen, Institute of Neuropathology, Goettingen, Germany
| | - B. Mollenhauer
- Paracelsus-Elena-Klinik, Kassel, Germany
- University Medical Center Goettingen, Institute of Neuropathology, Goettingen, Germany
| | - S. Novello
- Department of Medical Sciences, Section of Pharmacology, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy
- Neuroscience Center and National Institute of Neuroscience, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy
| | - M. Morari
- Department of Medical Sciences, Section of Pharmacology, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy
- Neuroscience Center and National Institute of Neuroscience, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy
| | - T. Leste-Lasserre
- INSERM, Neurocentre Magendie, U1215, Physiopathologie de la Plasticité Neuronale, F-33000 Bordeaux, France
| | - I. Trigo-Damas
- HM CINAC, HM Puerta del Sur and CEU–San Pablo University Madrid, E-28938 Mostoles, Spain
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain
| | - M. Goillandeau
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - C. Perier
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain
- Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)–Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain
| | - C. Estrada
- Clinical and Experimental Neuroscience Unit, School of Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain
- Institute of Research on Aging (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain
| | - N. Garcia-Carrillo
- Centro Experimental en Investigaciones Biomédica (CEIB), Universidad de Murcia, Murcia, Spain
| | - A. Recasens
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain
- Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)–Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain
| | - N. N. Vaikath
- Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Education City, Qatar
| | - O. M. A. El-Agnaf
- Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Education City, Qatar
| | - M. T. Herrero
- Clinical and Experimental Neuroscience Unit, School of Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain
- Institute of Research on Aging (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain
| | - P. Derkinderen
- INSERM, U1235, Nantes F-44035, France
- Nantes University, Nantes F-44035, France
- CHU Nantes, Department of Neurology, Nantes F-44093, France
| | - M. Vila
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain
- Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)–Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain
- Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona (UAB), Barcelona, Spain
- Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain
| | - J. A. Obeso
- HM CINAC, HM Puerta del Sur and CEU–San Pablo University Madrid, E-28938 Mostoles, Spain
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain
| | - B. Dehay
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - E. Bezard
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| |
Collapse
|
7
|
Affiliation(s)
- Daniel Moya
- Co-President the 14th International Congress of Shoulder and Elbow Surgery
| | - Gastón Maignón
- Co-President the 14th International Congress of Shoulder and Elbow Surgery
| | - Marcelo Vila
- President of the Argentinean Shoulder and Elbow Surgery Association
| |
Collapse
|
8
|
Martínez-González MA, Buil-Cosiales P, Corella D, Bulló M, Fitó M, Vioque J, Romaguera D, Martínez JA, Wärnberg J, López-Miranda J, Estruch R, Bueno-Cavanillas A, Arós F, Tur JA, Tinahones F, Serra-Majem L, Martín V, Lapetra J, Vázquez C, Pintó X, Vidal J, Daimiel L, Delgado-Rodríguez M, Matía P, Ros E, Fernández-Aranda F, Botella C, Portillo MP, Lamuela-Raventós RM, Marcos A, Sáez G, Gómez-Gracia E, Ruiz-Canela M, Toledo E, Alvarez-Alvarez I, Díez-Espino J, Sorlí JV, Basora J, Castañer O, Schröder H, Navarrete-Muñoz EM, Zulet MA, García-Rios A, Salas-Salvadó J, Corella D, Estruch R, Fitó M, Martínez-González MA, Ros E, Salas-Salvadó J, Babio N, Ros E, Sánchez-Tainta A, Martínez-González MA, Fitó M, Schröder H, Marcos A, Corella D, Wärnberg J, Martínez-González MA, Estruch R, Fernández-Aranda F, Botella C, Salas-Salvadó J, Razquin C, Bes-Rastrollo M, Sanchez Tainta A, Vázquez Z, SanJulian Aranguren B, Goñi E, Goñi L, Barrientos I, Canales M, Sayón-Orea MC, Rico A, Basterra Gortari J, Garcia Arellano A, Lecea-Juarez O, Carlos Cenoz-Osinaga J, Bartolome-Resano J, Sola-Larraza† A, Lozano-Oloriz E, Cano-Valles B, Eguaras S, Güeto V, Pascual Roquet-Jalmar E, Galilea-Zabalza I, Lancova H, Ramallal R, Garcia-Perez ML, Estremera-Urabayen V, Ariz-Arnedo MJ, Hijos-Larraz C, Fernandez Alfaro C, Iñigo-Martinez B, Villanueva Moreno R, Martin-Almendros S, Barandiaran-Bengoetxea L, Fuertes-Goñi C, Lezaun-Indurain A, Guruchaga-Arcelus MJ, Olmedo-Cruz O, Iñigo-Martínez B, Escriche-Erviti L, Ansorena-Ros R, Sanmatin-Zabaleta R, Apalategi-Lasa J, Villanueva-Telleria J, Hernández-Espinosa MM, Arroyo-Bergera I, Herrera-Valdez L, Dorronsoro-Dorronsoro L, González JI, Sorlí JV, Portolés O, Fernández-Carrión R, Ortega-Azorín C, Barragán R, Asensio EM, Coltell O, Sáiz C, Osma R, Férriz E, González-Monje I, Giménez-Fernández F, Quiles L, Carrasco P, San Onofre N, Carratalá-Calvo A, Valero-Barceló C, Antón F, Mir C, Sánchez-Navarro S, Navas J, González-Gallego I, Bort-Llorca L, Pérez-Ollero L, Giner-Valero M, Monfort-Sáez R, Nadal-Sayol J, Pascual-Fuster V, Martínez-Pérez M, Riera C, Belda MV, Medina A, Miralles E, Ramírez-Esplugues MJ, Rojo-Furió M, Mattingley G, Delgado MA, Pages MA, Riofrío Y, Abuomar L, Blasco-Lafarga N, Tosca R, Lizán L, Guillem-Saiz P, Valcarce AM, Medina MD, Monfort R, de Valcárcel S, Tormo N, Felipe-Román O, Lafuente S, Navío EI, Aldana G, Crespo JV, Llosa JL, González-García L, Raga-Marí R, Pedret Llaberia R, Gonzalez R, Sagarra Álamo R, París Palleja F, Balsells J, Roca JM, Basora Gallisa T, Vizcaino J, Llobet Alpizarte P, Anguera Perpiñá C, Llauradó Vernet M, Caballero C, Garcia Barco M, Morán Martínez MD, García Rosselló J, Del Pozo A, Poblet Calaf C, Arcelin Zabal P, Floresví X, Ciutat Benet M, Palau Galindo A, Cabré Vila JJ, Dolz Andrés F, Boj Casajuana J, Ricard M, Saiz F, Isach A, Sanchez Marin Martinez M, Bulló M, Babio N, Becerra-Tomás N, Mestres G, Basora J, Mena-Sánchez G, Barrubés Piñol L, Gil Segura M, Papandreou C, Rosique Esteban N, Chig S, Abellán Cano I, Ruiz García V, Salas-Huetos A, Hernandez P, Canudas S, Camacho-Barcia L, García-Gavilán J, Diaz A, Castañer O, Muñoz MA, Zomeño MD, Hernaéz A, Torres L, Quifer M, Llimona R, Gal LA, Pérez A, Farràs M, Elosua R, Marrugat J, Vila J, Subirana I, Pérez S, Muñoz MA, Goday A, Chillaron Jordan JJ, Flores Lerroux JA, Benaiges Boix D, Farré M, Menoyo E, Muñoz-Aguayo D, Gaixas S, Blanchart G, Sanllorente A, Soria M, Valussi J, Cuenca A, Forcano L, Pastor A, Boronat A, Tello S, Cabañero M, Franco L, Schröder H, De la Torre R, Medrano C, Bayó J, García MT, Robledo V, Babi P, Canals E, Soldevila N, Carrés L, Roca C, Comas MS, Gasulla G, Herraiz X, Martínez A, Vinyoles E, Verdú JM, Masague Aguade M, Baltasar Massip E, Lopez Grau M, Mengual M, Moldon V, Vila Vergaz M, Cabanes Gómez Ciurana R, Gili Riu M, Palomeras Vidal A, Garcia de la Hera M, González Palacios S, Torres Collado L, Valera Gran D, Compañ Gabucio L, Oncina Canovas A, Notario Barandiaran L, Orozco Beltran D, Pertusa Martínez S, Cloquell Rodrigo B, Hernándis Marsán MV, Asensio A, Altozano Rodado MC, Ballester Baixauli JJ, Fernándis Brufal N, Martínez Vergara MC, Román Maciá J, Candela García I, Pedro Cases Pérez E, Tercero Maciá C, Mira Castejón LA, de los Ángeles García García I, Zazo JM, Gisbert Sellés C, Sánchez Botella C, Fiol M, Moñino M, Colom A, Konieczna J, Morey M, Zamanillo R, Galmés AM, Pereira V, Martín MA, Yáñez A, Llobera J, Ripoll J, Prieto R, Grases F, Costa A, Fernández-Palomeque C, Fortuny E, Noris M, Munuera S, Tomás F, Fiol F, Jover A, Janer JM, Vallespir C, Mattei I, Feuerbach N, del Mar Sureda M, Vega S, Quintana L, Fiol A, Amador M, González S, Coll J, Moyá A, Abete I, Cantero I, Cristobo C, Ibero-Baraibar I, Lezáun Burgui MD, Goñi Ruiz N, Bartolomé Resano R, Cano Cáceres E, Elcarte López T, Echarte Osacain E, Pérez Sanz B, Blanco Platero I, Andueza Azcárate SA, Gimeno Aznar A, Ursúa Sesma E, Ojeda Bilbao B, Martinez Jarauta J, Ugalde Sarasa L, Rípodas Echarte B, Güeto Rubio MV, Fernández-Crehuet Navajas J, Gutiérrez Bedmar M, García Rodriguez A, Mariscal Larrubia A, Carnero Varo M, Muñoz Bravo C, Barón-López FJ, Fernández García JC, Pérez-Farinós N, Moreno-Morales N, del C Rodríguez-Martínez M, Pérez-López J, Benavente-Marín JC, Crespo Oliva E, Contreras Fernández E, Carmona González FJ, Carabaño Moral R, Torres Moreno S, Martín Ruíz MV, Alcalá Cornide M, Fuentes Gómez V, Criado García J, Jiménez Morales AI, Delgado Casado N, Ortiz Morales A, Torres Peña JD, Gómez Delgado FJ, Rodríguez Cantalejo F, Caballero Villaraso J, Alcalá JF, Peña Orihuela PJ, Quintana Navarro G, Casas R, Domenech M, Viñas C, Castro-Barquero S, Ruiz-León AM, Sadurní M, Frontana G, Villanueva P, Gual M, Soriano R, Camafort M, Sierra C, Sacanella E, Sala-Vila A, Cots JM, Sarroca I, García M, Bermúdez N, Pérez A, Duaso I, de la Arada A, Hernández R, Simón C, de la Poza MA, Gil I, Vila M, Iglesias C, Assens N, Amatller M, Rams LL, Benet T, Fernández G, Teruel J, Azorin A, Cubells M, López D, Llovet JM, Gómez ML, Climente P, de Paula L, Soto J, Carbonell C, Llor C, Abat X, Cama A, Fortuny M, Domingo C, Liberal AI, Martínez T, Yañez E, Nieto MJ, Pérez A, Lloret E, Carrazoni C, Belles AM, Olmos C, Ramentol M, Capell MJ, Casas R, Giner I, Muñoz A, Martín R, Moron E, Bonillo A, Sánchez G, Calbó C, Pous J, Massip M, García Y, Massagué MC, Ibañez R, Llaona J, Vidal T, Vizcay N, Segura E, Galindo C, Moreno M, Caubet M, Altirriba J, Fluxà G, Toribio P, Torrent E, Anton JJ, Viaplana A, Vieytes G, Duch N, Pereira A, Moreno MA, Pérez A, Sant E, Gené J, Calvillo H, Pont F, Puig M, Casasayas M, Garrich A, Senar E, Martínez A, Boix I, Sequeira E, Aragunde V, Riera S, Salgado M, Fuentes M, Martín E, Ubieto A, Pallarés F, Sala C, Abilla A, Moreno S, Mayor E, Colom T, Gaspar A, Gómez A, Palacios L, Garrigosa R, García Molina L, Riquelme Gallego B, Cano Ibañez N, Maldonado Calvo A, López Maldonado A, Garrido EM, Baena Dominguez A, García Jiménez F, Thomas Carazo E, Jesús Turnes González A, González Jiménez F, Padilla Ruiz F, Machado Santiago J, Martínez Bellón MD, Pueyos Sánchez A, Arribas Mir L, Rodríguez Tapioles R, Dorador Atienza F, Baena Camus L, Osorio Martos C, Rueda Lozano D, López Alcázar M, Ramos Díaz F, Cruz Rosales Sierra M, Alguacil Cubero P, López Rodriguez A, Guerrero García F, Tormo Molina J, Ruiz Rodríguez F, Rekondo J, Salaverria I, Alonso-Gómez A, Belló MC, Loma-Osorio A, Tojal L, Bruyel P, Goicolea L, Sorto C, Casi Casanellas A, Arnal Otero ML, Ortueta Martínez De Arbulo J, Vinagre Morgado J, Romeo Ollora J, Urraca J, Sarriegui Carrera MI, Toribio FJ, Magán E, Rodríguez A, Castro Madrid S, Gómez Merino MT, Rodríguez Jiménez M, Gutiérrez Jodra M, López Alonso B, Iturralde Iriso J, Pascual Romero C, Izquierdo De La Guerra A, Abbate M, Aguilar I, Angullo E, Arenas A, Argelich E, Bibiloni MM, Bisbal Y, Bouzas C, Busquets C, Capó X, Carreres S, De la Peña A, Gallardo L, Gámez JM, García B, García C, Julibert A, Llompart I, Mascaró CM, Mateos D, Montemayor S, Pons A, Ripoll T, Rodríguez T, Salaberry E, Sureda A, Tejada S, Ugarriza L, Valiño L, Bernal López MR, Macías González M, Ruiz Nava J, Fernández García JC, Muñoz Garach A, Vilches Pérez A, González Banderas A, Alcaide Torres J, Vargas Candela A, León Fernández M, Hernández Robles R, Santamaría Fernández S, Marín JM, Valdés Hernández S, Villalobos JC, Ortiz A, Álvarez-Pérez J, Díaz Benítez EM, Díaz-Collado F, Sánchez-Villegas A, Pérez-Cabrera J, Casañas-Quintana LT, García-Guerra RB, Bautista-Castaño I, Ruano-Rodríguez C, Sarmiento de la Fe F, García-Pastor JA, Macías-Gutiérrez B, Falcón-Sanabria I, Simón-García C, Santana-Santana AJ, Álvarez-Álvarez JB, Díaz-González BV, Castillo Anzalas JM, Sosa-Also RE, Medina-Ponce J, Abajo Olea S, Adlbi Sibai A, Aguado Arconada A, Álvarez L, Carriedo Ule E, Escobar Fernández M, Ferradal García JI, Fernández Vázquez JP, García González M, González Donquiles C, González Quintana C, González Rivero F, Lavinia Popescu M, López Gil JI, López de la Iglesia J, Marcos Delgado A, Merino Acevedo C, Reguero Celada S, Rodríguez Bul M, Vilorio-Marqués L, Santos-Lozano JM, Miró-Moriano L, Domínguez-Espinaco C, Vaquero-Díaz S, García-Corte FJ, Santos-Calonge A, Toro-Cortés C, Pelegrina-López N, Urbano-Fernández V, Ortega-Calvo M, Lozano-Rodríguez J, Rivera-Benítez I, Caballero-Valderrama M, Iglesias-Bonilla P, Román-Torres P, Corchado-Albalat Y, Mayoral-Sánchez E, de Cos AI, Gutierrez S, Artola S, Galdon A, Gonzalo I, Más S, Sierra R, Luca B, Prieto L, Galera A, Gimenez-Gracia M, Figueras R, Poch M, Freixedas R, Trias F, Sarasa I, Fanlo M, Lafuente H, Liceran M, Rodriguez-Sanchez A, Pallarols C, Monedero J, Corbella X, Corbella E, Altés A, Vinagre I, Mestres C, Viaplana J, Serra M, Vera J, Freitas T, Ortega E, Pla I, Ordovás JM, Micó V, Berninches L, Concejo MJ, Muñoz J, Adrián M, de la Fuente Y, Albertos C, Villahoz E, Cornejo ML, Gaforio JJ, Moraleda S, Liétor N, Peis JI, Ureña T, Rueda M, Ballesta MI, Moreno Lopera C, Aragoneses Isabel C, Sirur Flores MA, Ceballos de Diego M, Bescos Cáceres T, Peña Cereceda Y, Martínez Abad M, Cabrera Vela R, González Cerrajero M, Rubio Herrera MA, Torrego Ellacuría M, Barabash Bustelo A, Ortiz Ramos M, Garin Barrutia U, Baños R, García-Palacios A, Cerdá Micó C, Estañ Capell N, Iradi A, Fandos Sánchez M. Cohort Profile: Design and methods of the PREDIMED-Plus randomized trial. Int J Epidemiol 2018; 48:387-388o. [PMID: 30476123 DOI: 10.1093/ije/dyy225] [Citation(s) in RCA: 159] [Impact Index Per Article: 26.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/08/2018] [Indexed: 01/04/2023] Open
Affiliation(s)
- Miguel A Martínez-González
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Pilar Buil-Cosiales
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
- Atención Primaria, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain
| | - Dolores Corella
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine, University of Valencia, Valencia, Spain
| | - Monica Bulló
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Rovira i Virgili University, Department of Biochemistry and Biotechnology, Human Nutrition Unit, IISPV, Hospital Universitari Sant Joan de Reus, Reus, Spain
| | - Montserrat Fitó
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Mèdica (IMIM), Barcelona, Spain
| | - Jesús Vioque
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Miguel Hernandez University, ISABIAL-FISABIO, Alicante, Spain
| | - Dora Romaguera
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Clinical Epidemiology and Public Health Department, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain
| | - J Alfredo Martínez
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- University of Navarra, Department of Nutrition, Food Science and Physiology, IDISNA, Pamplona, Spain
| | - Julia Wärnberg
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Nursing, School of Health Sciences, University of Málaga-IBIMA, Málaga, Spain
| | - Jose López-Miranda
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain
| | - Ramón Estruch
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Internal Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Aurora Bueno-Cavanillas
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine, University of Granada, Granada, Spain
| | - Fernando Arós
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Cardiology, University Hospital Araba, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain
| | - Josep A Tur
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, Palma de Mallorca, Spain
| | - Francisco Tinahones
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Virgen de la Victoria Hospital, Department of Endocrinology, University of Málaga, Málaga, Spain
| | - Lluis Serra-Majem
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- University of Las Palmas de Gran Canaria, Research Institute of Biomedical and Health Sciences (IUIBS), Preventive Medicine Service, Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, Las Palmas, Spain
| | - Vicente Martín
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Institute of Biomedicine (IBIOMED), University of León, León, Spain
| | - Jose Lapetra
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain
| | - Clotilde Vázquez
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Endocrinology, Fundación Jiménez-Díaz, Madrid, Spain
| | - Xavier Pintó
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - Josep Vidal
- CIBER Diabetes y enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Endocrinology, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Lidia Daimiel
- Nutritional Genomics and Epigenomics Group, IMDEA Food, CEI UAM + CSIC, Madrid, Spain
| | - Miguel Delgado-Rodríguez
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Division of Preventive Medicine, Faculty of Medicine, University of Jaén, Jaén, Spain
| | - Pilar Matía
- Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain
| | - Emilio Ros
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Lipid Clinic, Department of Endocrinology and Nutrition, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain
| | - Fernando Fernández-Aranda
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Eating Disorders Unit, Department of Psychiatry, University Hospital of Bellvitge-IDIBELL, Hospitalet del Llobregat, Barcelona, Spain
| | - Cristina Botella
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Basic and Clinical Psychology and Psychobiology, Universitat Jaume I, Castellón de la Plana, Spain
| | - María Puy Portillo
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Nutrition and Food Science, Faculty of Pharmacy and Lucio Lascaray Research Center, Universidad del País Vasco (UPV/EHU), Vitoria, Spain
| | - Rosa M Lamuela-Raventós
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Nutrition, Food Science and Gastronomy, XaRTA, INSA, -UB, School of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain
| | - Ascensión Marcos
- Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), Madrid, Spain
| | - Guillermo Sáez
- Department of Biochemistry and Molecular Biology, Faculty of Medicine and Odontology, University Hospital Dr. Peset, University of Valencia, Valencia, Spain
| | | | - Miguel Ruiz-Canela
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
| | - Estefania Toledo
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
| | - Ismael Alvarez-Alvarez
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
| | - Javier Díez-Espino
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
- Atención Primaria, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain
| | - José V Sorlí
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine, University of Valencia, Valencia, Spain
| | - Josep Basora
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Rovira i Virgili University, Department of Biochemistry and Biotechnology, Human Nutrition Unit, IISPV, Hospital Universitari Sant Joan de Reus, Reus, Spain
| | - Olga Castañer
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Mèdica (IMIM), Barcelona, Spain
| | - Helmut Schröder
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Mèdica (IMIM), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Eva María Navarrete-Muñoz
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Miguel Hernandez University, ISABIAL-FISABIO, Alicante, Spain
| | - Maria Angeles Zulet
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- University of Navarra, Department of Nutrition, Food Science and Physiology, IDISNA, Pamplona, Spain
| | - Antonio García-Rios
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain
| | - Jordi Salas-Salvadó
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Rovira i Virgili University, Department of Biochemistry and Biotechnology, Human Nutrition Unit, IISPV, Hospital Universitari Sant Joan de Reus, Reus, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Gorka N, Lopez Guerra J, Krumina E, Marsiglia H, Vila M, Miró A, Garcia A, Gómez E, Azinovic I. EP-2260: High dose rate brachytherapy delivered in two fractions within one day for prostate cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32569-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
10
|
Rivas Lasarte M, Sans-Rosello J, Vila M, Tolppanen H, Lassus J, Lindholm M, Mebazaa A, Harjola VP, Sionis A. 4998Current use and impact on 30-day mortality of pulmonary artery catheter in cardiogenic shock patients: results from the CardShock Study. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.4998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M. Rivas Lasarte
- Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain
| | - J. Sans-Rosello
- Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain
| | - M. Vila
- Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain
| | - H. Tolppanen
- Helsinki University Central Hospital, Cardiology department, Helsinki, Finland
| | - J. Lassus
- Helsinki University Central Hospital, Cardiology department, Helsinki, Finland
| | - M. Lindholm
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | | | - V.-P. Harjola
- Helsinki University Central Hospital, Cardiology department, Helsinki, Finland
| | - A. Sionis
- Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain
| | | |
Collapse
|
11
|
Calvo P, Pairet S, Vila M, Losada J, Bowen J, Cirac R, Bulbena A, Holloway A, Fatjó J. Dog assisted therapy for teenagers with emotional and behavioural issues: A multicentre study. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.418] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionFurther research is still needed to demonstrate the benefits of animal-assisted therapy (AAT) for specific participant profiles, such as children with behavioural disorders.ObjectivesWe wanted to find out if AAT could be considered an efficient therapeutic strategy for the treatment of children with behavioural disorders.AimsWe wanted to study the effects of a preestablished AAT program on the behaviour of children with emotional and behavioural issues in 6 different reception centres for children under government guardianship.MethodsForty-five children (12 to 17 years old) with emotional and behavioural issues participated in a 14-session AAT program. Behavioural measures were those routinely scored as part of therapy; an observational report of 3 different problematic behaviours (such as impulsivity, lack of social skills or lack of personal recognition) was made twice a week for each child (with a score of frequency and intensity). A pre- and post-treatment “global behaviour score” was calculated for each child, as an average value of the 3 problematic behaviours measured during the month pre-treatment and the month post-treatment.ResultsThe 45 participants attended, on average, 72.8% of AAT sessions. Independent behaviour scores differed between the pre- and post-intervention evaluations (n = 135 behaviours) (Wilcoxon test; P < 0.0001). Based on the global behaviour score for each child (n = 45), significant change was found between pre- and post-intervention evaluations (Wilcoxon test; P = 0.0011).ConclusionsOur results suggest AAT could be a beneficial intervention for children with behavioural issues in terms of program adherence and behaviour improvement.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
12
|
Santos NF, Cicuéndez M, Holz T, Silva VS, Fernandes AJS, Vila M, Costa FM. Diamond-Graphite Nanoplatelet Surfaces as Conductive Substrates for the Electrical Stimulation of Cell Functions. ACS Appl Mater Interfaces 2017; 9:1331-1342. [PMID: 28001360 DOI: 10.1021/acsami.6b14407] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The nanocarbon allotropes constitute valid alternatives when designing control and actuation devices for electrically assisted tissue regeneration purposes, gathering among them important characteristics such as chemical inertness, biocompatibility, extreme mechanical properties, and, importantly, low and tailorable electrical resistivity. In this work, coatings of thin (100 nm) vertically aligned nanoplatelets composed of diamond (5 nm) and graphite were produced via a microwave plasma chemical vapor deposition (MPCVD) technique and used as substrates for electrical stimulation of MC3T3-E1 preosteoblasts. Increasing the amount of N2 up to 14.5 vol % during growth lowers the coatings' electrical resistivity by over 1 order of magnitude, triggers the nanoplatelet vertical growth, and leads to the higher crystalline quality of the nanographite phase. When preosteoblasts were cultured on these substrates and subjected to two consecutive daily cycles of 3 μA direct current stimulation, enhanced cell proliferation and metabolism were observed accompanied by high cell viability. Furthermore, in the absence of DC stimulation, alkaline phosphatase (ALP) activity is increased significantly, denoting an up-regulating effect of preosteoblastic maturation intrinsically exerted by the nanoplatelet substrates.
Collapse
Affiliation(s)
- N F Santos
- i3N and Physics Department, University of Aveiro , 3810-193 Aveiro, Portugal
| | - M Cicuéndez
- TEMA-NRG, Mechanical Engineering Department and CICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro , 3810-193 Aveiro, Portugal
| | - T Holz
- i3N and Physics Department, University of Aveiro , 3810-193 Aveiro, Portugal
| | - V S Silva
- CESAM, Biology Department, University of Aveiro , 3810-193 Aveiro, Portugal
| | - A J S Fernandes
- i3N and Physics Department, University of Aveiro , 3810-193 Aveiro, Portugal
| | - M Vila
- TEMA-NRG, Mechanical Engineering Department, University of Aveiro , 3810-193 Aveiro, Portugal
| | - F M Costa
- i3N and Physics Department, University of Aveiro , 3810-193 Aveiro, Portugal
| |
Collapse
|
13
|
Vila M, Díaz-Guerra C, Lorenz K, Piqueras J, Píš I, Magnano E, Munuera C, Alves E, García-Hernández M. Effects of thermal annealing on the structural and electronic properties of rare earth-implanted MoO3 nanoplates. CrystEngComm 2017. [DOI: 10.1039/c7ce00242d] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
14
|
Bissio E, Barbás MG, Bouzas MB, Cudolá A, Salomón H, Espínola L, Fernández Giuliano S, Kademián S, Mammana L, Ornani MLS, Ravasi G, Vila M, Zapiola I, Falistocco C. Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15. J Antimicrob Chemother 2016; 72:504-510. [PMID: 27789684 DOI: 10.1093/jac/dkw445] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2016] [Revised: 09/15/2016] [Accepted: 09/20/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND In Argentina, current national guidelines recommend starting with NNRTI-based regimens. Recently, there have been some local reports regarding concerning levels of NNRTI-transmitted resistance, but surveillance has never been carried out at a national level. OBJECTIVES To determine the prevalence of HIV drug resistance in people starting ART in Argentina using a WHO-proposed methodology. METHODS This was a cross-sectional, nationally representative study. Twenty-five antiretroviral-dispensing sites throughout the country were randomly chosen to enrol at least 330 persons starting ART, to generate a point prevalence estimate of resistance-associated mutations (RAMs) with a 5% CI (for the total population and for those without antiretroviral exposure). All consecutive patients older than 18 years starting or restarting ART in the chosen clinics were eligible. Samples were processed with Trugene and analysed using the Stanford algorithm. RESULTS Between August 2014 and March 2015, we obtained 330 samples from people starting ART. The mean ± SD age was 35 ± 11 years, 63.4% were male, 16.6% had prior antiretroviral exposure and the median (IQR) CD4 count was 275 cells/mm3 (106-461). The prevalence of RAMs found was 14% (±4%) for the whole population (3% NRTI-RAMs; 11% NNRTI-RAMs and 2% PI-RAMs) and 13% (±4%) for those without prior antiretroviral exposure (3%, 10% and 2%, respectively). The most common mutation was K103N. CONCLUSIONS This surveillance study showed concerning levels of HIV drug resistance in Argentina, especially to NNRTIs. Due to this finding, Argentina's Ministry of Health guidelines will change, recommending performing a resistance test for everyone before starting ART. If this is taken up properly, it also might function as a continuing surveillance tool.
Collapse
Affiliation(s)
- E Bissio
- Fundación Centro de Estudios Infectológicos (FUNCEI), Ciudad de Buenos Aires, Argentina
| | - M G Barbás
- Laboratorio Central de Córdoba, Ciudad de Córdoba, Argentina
| | - M B Bouzas
- Hospital Muñiz, Ciudad de Buenos Aires, Argentina
| | - A Cudolá
- Laboratorio Central de Córdoba, Ciudad de Córdoba, Argentina
| | - H Salomón
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina
| | - L Espínola
- Dirección de Sida, Ministerio de Salud de la Nación, Ciudad de Buenos Aires, Argentina
| | | | - S Kademián
- Laboratorio Central de Córdoba, Ciudad de Córdoba, Argentina
| | - L Mammana
- Hospital Muñiz, Ciudad de Buenos Aires, Argentina
| | - M L Suárez Ornani
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina
| | - G Ravasi
- Pan American Health Organization, Washington, DC, USA
| | - M Vila
- Pan American Health Organization, Ciudad de Buenos Aires, Argentina
| | - I Zapiola
- Hospital Muñiz, Ciudad de Buenos Aires, Argentina
| | - C Falistocco
- Dirección de Sida, Ministerio de Salud de la Nación, Ciudad de Buenos Aires, Argentina
| |
Collapse
|
15
|
Tortosa R, Soler P, Chinillach N, Ruiz C, Vila M, Sanchez M. EP-2012: Are there differences in quality prostate indicators among 9-Gy vs 15-Gy HDR brachytherapy boost? Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)33263-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Navarro C, Séguy L, Vila M, Birckel P. Bioequivalence study between two formulations of ciclosporin A (Cyclavance® oral solution and Atopica® soft capsules) following a single oral administration to dogs. BMC Vet Res 2016; 12:54. [PMID: 26970736 PMCID: PMC4789266 DOI: 10.1186/s12917-016-0669-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Accepted: 03/02/2016] [Indexed: 12/03/2022] Open
Abstract
Background Ciclosporin is a selective immunomodulator used for the treatment of atopic dermatitis in dogs. A new 100 mg/ml oral solution formulation (Cyclavance®, Virbac) was developed as a pharmaceutical equivalent to the marketed capsule formulations (Atopica®, Novartis Animal Health) containing 25, 50 mg, or 100 mg of ciclosporin A. The aim of this study was to assess and compare the pharmacokinetic profiles and bioequivalence of the two formulations following a single oral administration to dogs. This randomised, two-period, two-sequence, crossover bioequivalence study was conducted in 40 healthy dogs under fasting conditions. Each dog received either one 50 mg capsule of Atopica® or 0.5 ml of Cyclavance®. After dosing, blood samples were collected during a 48-h time period at 0, 0.5, 1, 2, 4, 6, 12, 24, 36 and 48 h. Blood ciclosporin A concentrations were measured by using an HPLC-MS/MS method. Cmax, Tmax, t1/2, AUC0-t, AUC0-∞ and Kel were determined for the two ciclosporin formulations. Bioequivalence was to be concluded if the 90 % confidence intervals were within the range of 80 % to 125 % for Cmax and AUC0-t. Dogs were monitored once daily throughout the study period for adverse effects. Results The 90 % confidence intervals for Cyclavance®/Atopica® mean ratios of the log-transformed pharmacokinetic variables Cmax and AUC0-t were within the conventional bioequivalence range of 80 % to 125 % (Point estimate: 101.2 % and 101.4 % respectively). Except for salivation reported after administration of both products, or vomiting and diarrhoea reported after Atopica® administration, both formulations were well tolerated in the 40 healthy dogs over the 48-h study period. Conclusions The two ciclosporin oral formulations demonstrated similar pharmacokinetic profiles and were found to be bioequivalent, and therefore, interchangeable.
Collapse
Affiliation(s)
- C Navarro
- Virbac, Medical Department, Carros, France.
| | | | - M Vila
- AmatsiAvogadro, Bioservices department, Fontenilles, France
| | - P Birckel
- AmatsiAvogadro, Bioservices department, Fontenilles, France
| |
Collapse
|
17
|
Vila M, Viñas L, Aguilar I, Toro C, Pérez A, Capel M. PS-055 The incidence of drug allergies in hospitalised patients. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
18
|
Duran-Cambra A, Sutil-Vega M, Fiol M, Núñez-Gil IJ, Vila M, Sans-Roselló J, Cinca J, Sionis A. Systematic review of the electrocardiographic changes in the takotsubo syndrome. Ann Noninvasive Electrocardiol 2014; 20:1-6. [PMID: 25367822 DOI: 10.1111/anec.12228] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Affiliation(s)
- A Duran-Cambra
- Cardiology Department, Hospital of the Holy Cross and Saint Paul, Biomedical Research Institute Sant Pau, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Huetos O, Bartolomé M, Aragonés N, Cervantes-Amat M, Esteban M, Ruiz-Moraga M, Pérez-Gómez B, Calvo E, Vila M, Castaño A. Serum PCB levels in a representative sample of the Spanish adult population: the BIOAMBIENT.ES project. Sci Total Environ 2014; 493:834-844. [PMID: 25000579 DOI: 10.1016/j.scitotenv.2014.06.077] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/21/2014] [Revised: 06/17/2014] [Accepted: 06/17/2014] [Indexed: 06/03/2023]
Abstract
This manuscript presents the levels of six indicator polychlorinated biphenyl (PCB) congeners (IUPAC nos. 28, 52, 101, 138, 153 and 180) in the serum of 1880 individuals from a representative sample of the Spanish working population recruited between March 2009 and July 2010. Three out of the six PCBs studied (180, 153 and 138) were quantified in more than 99% of participants. PCB 180 was the highest contributor, followed by PCBs 153 and 138, with relative abundances of 42.6%, 33.2% and 24.2%, respectively. In contrast, PCBs 28 and 52 were detected in only 1% of samples, whereas PCB 101 was detectable in 6% of samples. The geometric mean (GM) for ΣPCBs138/153/180 was 135.4 ng/g lipid (95% CI: 121.3-151.2 ng/g lipid) and the 95th percentile was 482.2 ng/g lipid. Men had higher PCB blood concentrations than women (GMs 138.9 and 129.9 ng/g lipid respectively). As expected, serum PCB levels increased with age and frequency of fish consumption, particularly in those participants younger than 30 years of age. The highest levels we found were for participants from the Basque Country, whereas the lowest concentrations were found for those from the Canary Islands. The Spanish population studied herein had similar levels to those found previously in Greece and southern Italy, lower levels than those in France and central Europe, and higher PCB levels than those in the USA, Canada and New Zealand. This paper provides the first baseline information regarding PCB exposure in the Spanish adult population on a national scale. The results will allow us to establish reference levels, follow temporal trends and identify high-exposure groups, as well as monitor implementation of the Stockholm Convention in Spain.
Collapse
Affiliation(s)
- O Huetos
- Environmental Toxicology, Centro Nacional de Sanidad Ambiental (CNSA), Instituto de Salud Carlos III, 28220 Madrid, Spain
| | - M Bartolomé
- Environmental Toxicology, Centro Nacional de Sanidad Ambiental (CNSA), Instituto de Salud Carlos III, 28220 Madrid, Spain
| | - N Aragonés
- National Centre for Epidemiology, Instituto de Salud Carlos III, 28029 Madrid, Spain; CIBER in Epidemiology and Public Health (CIBERESP), Spain
| | - M Cervantes-Amat
- National Centre for Epidemiology, Instituto de Salud Carlos III, 28029 Madrid, Spain; CIBER in Epidemiology and Public Health (CIBERESP), Spain
| | - M Esteban
- Environmental Toxicology, Centro Nacional de Sanidad Ambiental (CNSA), Instituto de Salud Carlos III, 28220 Madrid, Spain
| | | | - B Pérez-Gómez
- National Centre for Epidemiology, Instituto de Salud Carlos III, 28029 Madrid, Spain; CIBER in Epidemiology and Public Health (CIBERESP), Spain
| | - E Calvo
- Ibermutuamur, Ramirez de Arellano 27, Madrid, Spain
| | - M Vila
- Ibermutuamur, Ramirez de Arellano 27, Madrid, Spain
| | - A Castaño
- Environmental Toxicology, Centro Nacional de Sanidad Ambiental (CNSA), Instituto de Salud Carlos III, 28220 Madrid, Spain
| |
Collapse
|
20
|
Feito MJ, Vila M, Matesanz MC, Linares J, Gonçalves G, Marques PAAP, Vallet-Regí M, Rojo JM, Portolés MT. In vitro evaluation of graphene oxide nanosheets on immune function. J Colloid Interface Sci 2014; 432:221-8. [PMID: 25086397 DOI: 10.1016/j.jcis.2014.07.004] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2014] [Revised: 07/03/2014] [Accepted: 07/04/2014] [Indexed: 12/18/2022]
Abstract
HYPOTHESIS Graphene oxide (GO) has attracted the scientific community attention due to its novel properties and wide range of potential applications including hyperthermia cancer therapy. However, little is known about the GO effects on the immune function which involves both innate and adaptive defence mechanisms through the activation of different cell populations and secretion of several cytokines. The effect of different GO nanosheets designed for hyperthermia cancer therapy on macrophage and lymphocyte function should be determined before using GO for this application. EXPERIMENTS The effects of GO nanosheets with 1 (1-GOs) and 6 arms (6-GOs) of polyethylene glycol on RAW-264.7 macrophages and primary splenocytes (as approximation to the in vivo situation) were evaluated through the proinflammatory cytokine secretion and the modulation of cell proliferation in the presence of specific stimuli for either T-lymphocytes (concanavalin A, anti-CD3 antibody) or B-lymphocytes/macrophages (lipopolysaccharide). FINDINGS 6-GOs significantly increased the secretion of TNF-α by RAW-264.7 macrophages without alteration of IL-6 and IL-1β levels. The treatment of primary splenocytes with 1-GOs and 6-GOs in the presence of concanavalin A, anti-CD3 antibody and lipopolysaccharide, produced significant dose-dependent decreases of cell proliferation and IL-6 levels, revealing weak inflammatory properties of GOs which are favourable for hyperthermia cancer therapy.
Collapse
Affiliation(s)
- M J Feito
- Department of Biochemistry and Molecular Biology I, Faculty of Chemistry, Universidad Complutense, 28040 Madrid, Spain.
| | - M Vila
- Department of Inorganic and Bioinorganic Chemistry, Faculty of Pharmacy, UCM, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, 28040 Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Spain; TEMA-NRD, Mechanical Engineering Department and Aveiro Institute of Nanotechnology (AIN), University of Aveiro, 3810-193 Aveiro, Portugal.
| | - M C Matesanz
- Department of Biochemistry and Molecular Biology I, Faculty of Chemistry, Universidad Complutense, 28040 Madrid, Spain.
| | - J Linares
- Department of Biochemistry and Molecular Biology I, Faculty of Chemistry, Universidad Complutense, 28040 Madrid, Spain.
| | - G Gonçalves
- TEMA-NRD, Mechanical Engineering Department and Aveiro Institute of Nanotechnology (AIN), University of Aveiro, 3810-193 Aveiro, Portugal.
| | - P A A P Marques
- TEMA-NRD, Mechanical Engineering Department and Aveiro Institute of Nanotechnology (AIN), University of Aveiro, 3810-193 Aveiro, Portugal.
| | - M Vallet-Regí
- Department of Inorganic and Bioinorganic Chemistry, Faculty of Pharmacy, UCM, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, 28040 Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Spain.
| | - J M Rojo
- Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas, CSIC, 28040 Madrid, Spain.
| | - M T Portolés
- Department of Biochemistry and Molecular Biology I, Faculty of Chemistry, Universidad Complutense, 28040 Madrid, Spain.
| |
Collapse
|
21
|
Barallobre MJ, Perier C, Bové J, Laguna A, Delabar JM, Vila M, Arbonés ML. DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease. Cell Death Dis 2014; 5:e1289. [PMID: 24922073 PMCID: PMC4611726 DOI: 10.1038/cddis.2014.253] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Revised: 04/22/2014] [Accepted: 05/08/2014] [Indexed: 12/18/2022]
Abstract
In the brain, programmed cell death (PCD) serves to adjust the numbers of the different types of neurons during development, and its pathological reactivation in the adult leads to neurodegeneration. Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) is a pleiotropic kinase involved in neural proliferation and cell death, and its role during brain growth is evolutionarily conserved. Human DYRK1A lies in the Down syndrome critical region on chromosome 21, and heterozygous mutations in the gene cause microcephaly and neurological dysfunction. The mouse model for DYRK1A haploinsufficiency (the Dyrk1a(+/-) mouse) presents neuronal deficits in specific regions of the adult brain, including the substantia nigra (SN), although the mechanisms underlying these pathogenic effects remain unclear. Here we study the effect of DYRK1A copy number variation on dopaminergic cell homeostasis. We show that mesencephalic DA (mDA) neurons are generated in the embryo at normal rates in the Dyrk1a haploinsufficient model and in a model (the mBACtgDyrk1a mouse) that carries three copies of Dyrk1a. We also show that the number of mDA cells diminishes in postnatal Dyrk1a(+/-) mice and increases in mBACtgDyrk1a mice due to an abnormal activity of the mitochondrial caspase9 (Casp9)-dependent apoptotic pathway during the main wave of PCD that affects these neurons. In addition, we show that the cell death induced by 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP), a toxin that activates Casp9-dependent apoptosis in mDA neurons, is attenuated in adult mBACtgDyrk1a mice, leading to an increased survival of SN DA neurons 21 days after MPTP intoxication. Finally, we present data indicating that Dyrk1a phosphorylation of Casp9 at the Thr125 residue is the mechanism by which this kinase hinders both physiological and pathological PCD in mDA neurons. These data provide new insight into the mechanisms that control cell death in brain DA neurons and they show that deregulation of developmental apoptosis may contribute to the phenotype of patients with imbalanced DYRK1A gene dosage.
Collapse
Affiliation(s)
- M J Barallobre
- Department of Developmental Biology, Instituto de Biología Molecular de Barcelona, CSIC, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - C Perier
- Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute and Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain
| | - J Bové
- Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute and Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain
| | - A Laguna
- Department of Developmental Biology, Instituto de Biología Molecular de Barcelona, CSIC, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - J M Delabar
- Unité de Biologie Fonctionnelle et Adaptative, EAC4413 CNRS, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - M Vila
- Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute and Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain
- Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona (UAB), Barcelona, Spain
- Catalan Institute for Research and Advanced Studies (ICREA), Barcelona, Spain
| | - M L Arbonés
- Department of Developmental Biology, Instituto de Biología Molecular de Barcelona, CSIC, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain
| |
Collapse
|
22
|
Vila M, Matesanz MC, Gonçalves G, Feito MJ, Linares J, Marques PAAP, Portolés MT, Vallet-Regi M. Triggering cell death by nanographene oxide mediated hyperthermia. Nanotechnology 2014; 25:035101. [PMID: 24346084 DOI: 10.1088/0957-4484/25/3/035101] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Graphene oxide (GO) has been proposed as an hyperthermia agent for anticancer therapies due to its near-infrared (NIR) optical absorption ability which, with its small two-dimensional size, could have a unique performance when compared to that of any other nanoparticle. Nevertheless, attention should be given to the hyperthermia route and the kind of GO-cell interactions induced in the process. The hyperthermia laser irradiation parameters, such as exposure time and laser power, were investigated to control the temperature rise and consequent damage in the GOs containing cell culture medium. The type of cell damage produced was evaluated as a function of these parameters. The results showed that cell culture temperature (after irradiating cells with internalized GO) increases preferentially with laser power rather than with exposure time. Moreover, when laser power is increased, necrosis is the preferential cell death leading to an increase of cytokine release to the medium.
Collapse
Affiliation(s)
- M Vila
- Department of Inorganic and Bioinorganic Chemistry, Faculty of Pharmacy, UCM, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, E-28040-Madrid, Spain. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Spain
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Vila M, Robles H, Ciudad C, Olea PP, Baglione V. PERMANENT GENETIC RESOURCES: Isolation and characterization of 12 microsatellite markers in the middle-spotted woodpecker (Dendrocopos medius). Mol Ecol Resour 2013; 8:415-7. [PMID: 21585807 DOI: 10.1111/j.1471-8286.2007.01976.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Twelve polymorphic microsatellite loci were developed for Dendrocopos medius. Polymorphism was assessed for 27 individuals from the southwesternmost population of this woodpecker species. The number of alleles per locus ranged from three to seven, with observed heterozygosity values from 0.444 to 0.852. Genotypic frequencies conformed to Hardy-Weinberg equilibrium, and no evidence for linkage disequilibrium was observed. Multilocus genotypes resulting from this set of markers will be useful to determine genetic diversity and differentiation within and among habitat patches inhabited by D. medius. Three of the loci were polymorphic for Picoides articus.
Collapse
Affiliation(s)
- M Vila
- Department of Molecular and Cell Biology, Faculty of Sciences, University of A Coruna, Campus Zapateira, E-15008, A Coruna, Spain
| | | | | | | | | |
Collapse
|
24
|
Remón N, Vila M, Galán P, Naveira H. Isolation and characterization of polymorphic microsatellite markers in Iberolacerta monticola, and cross-species amplification in Iberolacerta galani and Zootoca vivipara. Mol Ecol Resour 2013; 8:1351-3. [PMID: 21586043 DOI: 10.1111/j.1755-0998.2008.02271.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Fourteen polymorphic microsatellite loci are described for the Iberian rock lizard, Iberolacerta monticola. Genetic variation in a sample of 20 individuals from Piornedo (northwestern Spain) was quantified both by the number of alleles per locus, which ranged from six to 13, and by the expected frequency of heterozygotes under random mating (heterozygosity), which ranged from 0.761 to 0.902. Single locus and global exclusion probabilities were also computed, and indicate a high power of these markers for paternity assignments and mating system studies of I. monticola. All the analysed loci were also polymorphic in Iberolacerta galani, but only seven in Zootoca vivipara.
Collapse
Affiliation(s)
- N Remón
- Departamento de Bioloxía Celular e Molecular, Universidade da Coruña, Campus A Zapateira, E-15008, A Coruña, Spain Departamento de Bioloxía Animal, Bioloxía Vexetal e Ecoloxía, Universidade da Coruña, Campus A. Zapateira, E-15008, A Coruña, Spain
| | | | | | | |
Collapse
|
25
|
Krumina E, Nagore G, Vila M, Lozano J, Garcia A, Azinovic I. HDR brachytherapy as monotherapy for prostate cancer: Preliminary toxicity data. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
26
|
Ralón G, Rossi D, Vila M, Latorre L, Bastos FI, Caiaffa WT. [From local studies to a regional perspective: pooled analysis of secondary data in a collaborative project on vulnerabilities associated with drug use in Argentina, Brazil and Uruguay (1998-2004)]. Salud Colect 2013; 8:229-46. [PMID: 23681457 DOI: 10.1590/s1851-82652012000400002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2012] [Accepted: 08/09/2012] [Indexed: 11/21/2022] Open
Abstract
This paper develops the methodological principles of pooled analysis design, using it to study situations of vulnerability among drug users at a regional level. Data from thirteen cross-sectional studies carried out in Argentina, Brazil and Uruguay between 1998 and 2004 were integrated. A critical review of the concept of data matrix which identifies four structural components, allowed us to: define the units of analysis spanning the different original populations; identify a core of common variables (social and demographic characteristics, drug use, sexual practices, serology of blood-borne and sexually transmitted diseases) with their respective values; examine the indicators, dimensions and procedures used to measure the variables; and establish their compatibility with a thematic and comparative analysis of data collection tools. The main result was a new data matrix with 3,534 cases. Multidisciplinary collaboration between teams and institutions from the three countries made it possible to maximize the available sources in order to analyze characteristics of the local contexts and of the overall regional.
Collapse
Affiliation(s)
- Gonzalo Ralón
- Instituto Gino Germani, Universidad de Buenos Aires, Argentina.
| | | | | | | | | | | |
Collapse
|
27
|
Ramoneda M, Foncuberta M, Simón M, Sabaté S, Ferrer M, Herrera S, Landa B, Musté N, Martí R, Trabado V, Carbonell O, Vila M, Espelt M, Ramírez B, Durán J. Prevalence of verotoxigenic Escherichia coli
O157 (VTEC O157) and compliance with microbiological safety standards in bovine carcasses from an industrial beef slaughter plant. Lett Appl Microbiol 2013; 56:408-13. [DOI: 10.1111/lam.12062] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2012] [Revised: 02/08/2013] [Accepted: 02/24/2013] [Indexed: 11/27/2022]
Affiliation(s)
- M. Ramoneda
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - M. Foncuberta
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
- CIBER of Epidemiology and Public Health (CIBERESP); Madrid Spain
| | - M. Simón
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - S. Sabaté
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - M.D. Ferrer
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - S. Herrera
- Centro Nacional de Microbiología (National Center for Microbiology); Instituto de Salud Carlos III; Madrid Spain
| | - B. Landa
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - N. Musté
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - R. Martí
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - V. Trabado
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - O. Carbonell
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - M. Vila
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - M. Espelt
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - B. Ramírez
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| | - J. Durán
- Agència de Salut Pública de Barcelona (ASPB Public Health Agency of Barcelona); Barcelona Spain
| |
Collapse
|
28
|
Sintas C, Carreño O, Corominas R, Serra SA, Vila M, Fernández-Castillo N, Toma C, Pons R, Llaneza M, Sobrido MJ, Grinberg D, Valverde MA, Fernández-Fernández JM, Macaya A, Cormand B. Screening of cacna1a and ATP1A2 genes in hemiplegic migraine: clinical, genetic and functional studies. J Headache Pain 2013. [PMCID: PMC3620192 DOI: 10.1186/1129-2377-14-s1-p26] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
29
|
Ralón G, Rossi D, Vila M, Latorre L, Bastos FI, Caiaffa WT. From local studies to a regional perspective: pooled analysis of secondary data in a collaborative project on vulnerabilities associated with drug use in Argentina, Brazil and Uruguay (1998-2004). Salud Colect 2012; 8:229-246. [PMID: 23681457 DOI: 10.18294/sc.2012.164] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2012] [Accepted: 08/09/2012] [Indexed: 11/24/2022] Open
Abstract
This paper develops the methodological principles of pooled analysis design, using it to study situations of vulnerability among drug users at a regional level. Data from thirteen cross-sectional studies carried out in Argentina, Brazil and Uruguay between 1998 and 2004 were integrated. A critical review of the concept of data matrix which identifies four structural components, allowed us to: define the units of analysis spanning the different original populations; identify a core of common variables (social and demographic characteristics, drug use, sexual practices, serology of blood-borne and sexually transmitted diseases) with their respective values; examine the indicators, dimensions and procedures used to measure the variables; and establish their compatibility with a thematic and comparative analysis of data collection tools. The main result was a new data matrix with 3,534 cases. Multidisciplinary collaboration between teams and institutions from the three countries made it possible to maximize the available sources in order to analyze characteristics of the local contexts and of the overall regional.
Collapse
Affiliation(s)
- Gonzalo Ralón
- Licenciado en Sociología. Investigador, Intercambios Asociación Civil. Investigador, Instituto Gino Germani, Universidad de Buenos Aires, Argentina.
| | - Diana Rossi
- Trabajadora Social. Especialista en Problemáticas Sociales Infanto-juveniles. Coordinadora, Área de Investigación, Intercambios Asociación Civil, Buenos Aires, Argentina.
| | - Marcelo Vila
- Médico. Especialista en Clínica Médica y Epidemiología. Asesor médico e investigador, Intercambios Asociación Civil, Buenos Aires, Argentina.
| | - Laura Latorre
- Licenciada en Sociología. Instituto de Investigación y Desarrollo Social (IDES), Montevideo, Uruguay.
| | - Francisco Inácio Bastos
- Médico. Doctor en Salud Pública. Investigador, Fundação Oswaldo Cruz, Río de Janeiro, Brasil.
| | - Waleska Teixeira Caiaffa
- Médica. Doctora en Ciencias. Directora del Observatório de Saúde Urbana & Grupo de Pesquisas em Epidemiologia, Faculdade de Medicina, Universidade Federal de Minas Gerais. Belo Horizonte, Brasil.
| |
Collapse
|
30
|
Benito N, Mirelis B, Luz Gálvez M, Vila M, López-Contreras J, Cotura A, Pomar V, March F, Navarro F, Coll P, Gurguí M. Outbreak of Pseudomonas fluorescens bloodstream infection in a coronary care unit. J Hosp Infect 2012; 82:286-9. [PMID: 23103246 DOI: 10.1016/j.jhin.2012.09.008] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2012] [Accepted: 09/06/2012] [Indexed: 02/05/2023]
Abstract
An outbreak of Pseudomonas fluorescens infection in six patients in a coronary care unit was associated with a source not previously reported, namely the ice bath used for cardiac output determinations. Outbreaks of pseudobacteraemia caused by P. fluorescens and occasional blood transfusion-associated bloodstream infection (BSI) have been described. However, during the last two decades, two outbreaks of P. fluorescens BSI have been described and this article reports a third. Isolation of P. fluorescens in blood cultures must alert clinicians to the possibility of contamination of infusate, lock solutions or catheter flush.
Collapse
Affiliation(s)
- N Benito
- Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Vila M, Portolés MT, Marques PAAP, Feito MJ, Matesanz MC, Ramírez-Santillán C, Gonçalves G, Cruz SMA, Nieto A, Vallet-Regi M. Cell uptake survey of pegylated nanographene oxide. Nanotechnology 2012; 23:465103. [PMID: 23093209 DOI: 10.1088/0957-4484/23/46/465103] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Graphene and more specifically, nanographene oxide (GO) has been proposed as a highly efficient antitumoral therapy agent. Nevertheless, its cell uptake kinetics, its influence in different types of cells and the possibility of controlling cellular internalization timing, is still a field that remains unexplored. Herein, different cell types have been cultured in vitro for several incubation periods in the presence of 0.075 mg ml(-1) pegylated GO solutions. GO uptake kinetics revealed differences in the agent's uptake amount and speed as a function of the type of cell involved. Osteoblast-like cells GO uptake is higher and faster without resulting in greater cell membrane damage. Moreover, the dependence on the commonly used PEG nature (number of branches) also influences the viability and cell uptake speed. These facts play an important role in the future definition of timing parameters and selective cell uptake control in order to achieve an effective therapy.
Collapse
Affiliation(s)
- M Vila
- Inorganic and Bioinorganic Chemistry Department, Universidad Complutense de Madrid, 28040, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Gil-Albarova J, Vila M, Badiola-Vargas J, Sánchez-Salcedo S, Herrera A, Vallet-Regi M. In vivo osteointegration of three-dimensional crosslinked gelatin-coated hydroxyapatite foams. Acta Biomater 2012; 8:3777-83. [PMID: 22728682 DOI: 10.1016/j.actbio.2012.06.019] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Revised: 06/04/2012] [Accepted: 06/13/2012] [Indexed: 10/28/2022]
Abstract
The main requirement of bone regenerative scaffolds is to enhance the chemical reactions leading to the formation of new bone while providing a proper surface for tissue in-growth as well as a suitable degradation rate. Calcium phosphate ceramics are conformed by different shaping methods. One requirement is to design implants and scaffolds with suitable shapes and sizes, but also with interconnected porosity to ensure bone oxygenation and angiogenesis. In this work we present the in vivo performance of hierarchically arranged glutaraldehyde crosslinked, gelatin-coated nanocrystalline hydroxyapatite (HABP) scaffolds (1-400 μm), with high potential as bone regenerators and excellent osteointegration performance, as well as an appropriate bioresorption rate. 6×10 mm bone defects were made in the lateral aspect of both distal femoral epiphysis of 15 mature (9 months old) male New Zealand rabbits. The bone defect in the left femur was then filled by using HABP foam cylinders, allowing the surgeon to carve the appropriate shape for a particular bone defect with high stability intra-operatively. The foam becomes swollen with body fluid and fills the cavity, ensuring good fixation without the need for a cement. Histological and radiographical studies after 4 months implantation showed healing of all treated bone defects, with bone integration of the HABP foam cylinders and bone conduction over the surface. This in vivo behaviour offers promising results as a scaffold for clinical applications, mainly in orthopaedics and dentistry.
Collapse
|
33
|
Ramonet D, Perier C, Recasens A, Dehay B, Bové J, Costa V, Scorrano L, Vila M. Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death Differ 2012; 20:77-85. [PMID: 22858546 DOI: 10.1038/cdd.2012.95] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Mitochondrial complex I dysfunction has long been associated with Parkinson's disease (PD). Recent evidence suggests that mitochondrial involvement in PD may extend beyond a sole respiratory deficit and also include perturbations in mitochondrial fusion/fission or ultrastructure. Whether and how alterations in mitochondrial dynamics may relate to the known complex I defects in PD is unclear. Optic atrophy 1 (OPA1), a dynamin-related GTPase of the inner mitochondrial membrane, participates in mitochondrial fusion and apoptotic mitochondrial cristae remodeling. Here we show that complex I inhibition by parkinsonian neurotoxins leads to an oxidative-dependent disruption of OPA1 oligomeric complexes that normally keep mitochondrial cristae junctions tight. As a consequence, affected mitochondria exhibit major structural abnormalities, including cristae disintegration, loss of matrix density and swelling. These changes are not accompanied by mitochondrial fission but a mobilization of cytochrome c from cristae to intermembrane space, thereby lowering the threshold for activation of mitochondria-dependent apoptosis by cell death agonists in compromised neurons. All these pathogenic changes, including mitochondrial structural remodeling and dopaminergic neurodegeneration, are abrogated by OPA1 overexpression, both in vitro and in vivo. Our results identify OPA1 as molecular link between complex I deficiency and alterations in mitochondrial dynamics machinery and point to OPA1 as a novel therapeutic target for complex I cytopathies, such as PD.
Collapse
Affiliation(s)
- D Ramonet
- Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute-CIBERNED, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Vila M, Cicuéndez M, Sánchez-Marcos J, Fal-Miyar V, Manzano M, Prieto C, Vallet-Regi M. Electrical stimuli to increase cell proliferation on carbon nanotubes/mesoporous silica composites for drug delivery. J Biomed Mater Res A 2012; 101:213-21. [PMID: 22847920 DOI: 10.1002/jbm.a.34325] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2012] [Revised: 07/08/2012] [Accepted: 06/21/2012] [Indexed: 12/21/2022]
Abstract
The development of smart materials as bone implants is nowadays a challenging task to optimize their fast osteointegration. Nevertheless, no attempts have been done in joining the possibility of using electrical stimulation and drug delivery together in a material intended for bone tissue engineering. Moreover, the use of this synergy to induce bone healing is still limited until novel drug reservoirs material formulations allow an efficient applicability of the electrical stimuli. Herein, we present the biological response of osteoblasts cells, cultured over carbon nanotubes-mesoporous silica composites while exposed to external electrical stimulus. Moreover, its ability to function as drug delivery systems is also demonstrated. Bone cell metabolism was stimulated and mitochondrial activity was increased up to seven times in the presence of these composites under electrical stimulus, suggesting their potential application in bone regeneration processes.
Collapse
Affiliation(s)
- M Vila
- Department of Inorganic and Bioinorganic Chemistry, Universidad Complutense de Madrid, Madrid 28040, Spain.
| | | | | | | | | | | | | |
Collapse
|
35
|
Ravasi G, Jack N, Alonso Gonzalez M, Sued O, Pérez-Rosales MD, Gomez B, Vila M, Riego AD, Ghidinelli M. Progress of implementation of the World Health Organization strategy for HIV drug resistance control in Latin America and the Caribbean. Rev Panam Salud Publica 2012; 30:657-62. [PMID: 22358418 DOI: 10.1590/s1020-49892011001200026] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2011] [Accepted: 09/09/2011] [Indexed: 11/22/2022] Open
Abstract
By the end of 2010, Latin America and the Caribbean (LAC) achieved 63% antiretroviral treatment (ART) coverage. Measures to control HIV drug resistance (HIVDR) at the country level are recommended to maximize the efficacy and sustainability of ART programs. Since 2006, the Pan American Health Organization has supported implementation of the World Health Organization (WHO) strategy for HIVDR prevention and assessment through regional capacity-building activities and direct technical cooperation in 30 LAC countries. By 2010, 85 sites in 19 countries reported early warning indicators, providing information about the extent of potential drivers of drug resistance at the ART site. In 2009, 41.9% of sites did not achieve the WHO target of 100% appropriate first-line prescriptions; 6.3% still experienced high rates (> 20%) of loss to follow-up, and 16.2% had low retention of patients (< 70%) on first-line prescriptions in the first year of treatment. Stock-outs of antiretroviral drugs occurred at 22.7% of sites. Haiti, Guyana, and the Mesoamerican region are planning and implementing WHO HIVDR monitoring surveys or threshold surveys. New HIVDR surveillance tools for concentrated epidemics would promote further scale-up. Extending the WHO HIVDR lab network in Latin America is key to strengthening regional lab capacity to support quality assured HIVDR surveillance. The WHO HIVDR control strategy is feasible and can be rolled out in LAC. Integrating HIVDR activities in national HIV care and treatment plans is key to ensuring the sustainability of this strategy.
Collapse
|
36
|
Errando CL, Navarro L, Vila M, Pallardó MA. Anesthetic management of a patient diagnosed with CADASIL (cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy). ACTA ACUST UNITED AC 2012; 59:102-6. [PMID: 22480557 DOI: 10.1016/j.redar.2012.02.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2011] [Accepted: 02/06/2012] [Indexed: 10/28/2022]
Abstract
CADASIL (cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leu-koencephalopathy) is an infrequent inherited disease that could have anesthetic implica-tions. However these have rarely been reported. We present a male patient previously diagnosed with CADASIL, who had suffered an ischemic vascular cerebral accident with a MRI compatible with leukoencephalopathy, and who was dependent for daily activities, and sustained dementia, mood alterations, apathy, and urine incontinence. He had famil-ial antecedents of psychiatric symptoms and ischemic stroke events in several relatives including his father, two brothers and one sister. He was scheduled for arthrodesis of the left knee because of multiple infectious complications of prosthetic knee surgery. He was under clopidogrel treatment which was withdrawn seven days before surgery. The pro-cedure was performed under combined spinal-epidural anesthesia, intraoperative seda-tion with midazolam, and postoperative multimodal analgesia including epidural patient controlled analgesia. The perioperative management was uneventful and we outline the adequacy of managing these patients under regional anesthesia and analgesia, as these permit to maintain hemodynamic stability leading to adequate cerebral perfusion, key to avoid an increase in the effects of the chronic arteriopathy patients with CADASIL sustain.
Collapse
Affiliation(s)
- C L Errando
- Servicio de Anestesiología, Reanimación y Tratamiento del Dolor, Consorcio Hospital General Universitario de Valencia, Valencia, España
| | | | | | | |
Collapse
|
37
|
Sánchez-Danés A, Consiglio A, Richaud Y, Rodríguez-Pizà I, Dehay B, Edel M, Bové J, Memo M, Vila M, Raya A, Izpisua Belmonte JC. Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. Hum Gene Ther 2011; 23:56-69. [PMID: 21877920 DOI: 10.1089/hum.2011.054] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC) offer great hope for in vitro modeling of Parkinson's disease (PD), as well as for designing cell-replacement therapies. To realize these opportunities, there is an urgent need to develop efficient protocols for the directed differentiation of hESC/iPSC into dopamine (DA) neurons with the specific characteristics of the cell population lost to PD, i.e., A9-subtype ventral midbrain DA neurons. Here we use lentiviral vectors to drive the expression of LMX1A, which encodes a transcription factor critical for ventral midbrain identity, specifically in neural progenitor cells. We show that clonal lines of hESC engineered to contain one or two copies of this lentiviral vector retain long-term self-renewing ability and pluripotent differentiation capacity. Greater than 60% of all neurons generated from LMX1A-engineered hESC were ventral midbrain DA neurons of the A9 subtype, compared with ∼10% in green fluorescent protein-engineered controls, as judged by specific marker expression and functional analyses. Moreover, DA neuron precursors differentiated from LMX1A-engineered hESC were able to survive and differentiate when grafted into the brain of adult mice. Finally, we provide evidence that LMX1A overexpression similarly increases the yield of DA neuron differentiation from human iPSC. Taken together, our data show that stable genetic engineering of hESC/iPSC with lentiviral vectors driving controlled expression of LMX1A is an efficient way to generate enriched populations of human A9-subtype ventral midbrain DA neurons, which should prove useful for modeling PD and may be helpful for designing future cell-replacement strategies.
Collapse
Affiliation(s)
- A Sánchez-Danés
- 1 Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
de la Vega M, Díaz E, Vila M, León R. Isolation of a new strain of Picochlorum sp and characterization of its potential biotechnological applications. Biotechnol Prog 2011; 27:1535-43. [DOI: 10.1002/btpr.686] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2011] [Revised: 07/04/2011] [Indexed: 11/07/2022]
|
39
|
Vila M, Sánchez-Salcedo S, Cicuéndez M, Izquierdo-Barba I, Vallet-Regí M. Novel biopolymer-coated hydroxyapatite foams for removing heavy-metals from polluted water. J Hazard Mater 2011; 192:71-77. [PMID: 21616595 DOI: 10.1016/j.jhazmat.2011.04.100] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2010] [Revised: 04/25/2011] [Accepted: 04/26/2011] [Indexed: 05/30/2023]
Abstract
3D-macroporous biopolymer-coated hydroxyapatite (HA) foams have been developed as potential devices for the treatment of lead, cadmium and copper contamination of consumable waters. These foams have exhibited a fast and effective ion metal immobilization into the HA structure after an in vitro treatment mimicking a serious water contamination case. To improve HA foam stability at contaminated aqueous solutions pH, as well as its handling and shape integrity the 3D-macroporous foams have been coated with biopolymers polycaprolactone (PCL) and gelatine cross-linked with glutaraldehyde (G/Glu). Metal ion immobilization tests have shown higher and fast heavy metals captured as function of hydrophilicity rate of biopolymer used. After an in vitro treatment, foam morphology integrity is guaranteed and the uptake of heavy metal ions rises up to 405 μmol/g in the case of Pb(2+), 378 μmol/g of Cu(2+) and 316 μmol/g of Cd(2+). These novel materials promise a feasible advance in development of new, easy to handle and low cost water purifying methods.
Collapse
Affiliation(s)
- M Vila
- Inorganic and BioInorganic Chemistry Department, Pharmacy Faculty, Universidad Complutense de Madrid, Plaza de Ramón y Cajal s/n, 28040 Madrid, Spain
| | | | | | | | | |
Collapse
|
40
|
Díaz O, Esparza JM, Plaza M, Vila M. [Comments on the article "Hypotensive resuscitation of the polytrauma patient with hemorrhagic shock"]. Rev Esp Anestesiol Reanim 2011; 58:458-460. [PMID: 22046870 DOI: 10.1016/s0034-9356(11)70112-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
41
|
Arias F, Guerrero D, Gomez Dorronsoro ML, Montes M, Vera R, Asin G, Monzon F, Balen E, Armendariz P, Vila M, Chicata V, Viúdez A, Bandres E, Garcia-Foncillas J, DomÃnguez MA. Correlation of tumor regression grade (TRG), circumferential margin (CM), and epidermal growth factor receptor expression with disease-free survival (DFS) in locally advanced rectal cancer patients (LARC) treated with preoperative radiochemotherapy (preCh-RT). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Iturre EV, Romero P, Chicata V, Pellejero S, Lozares S, Vila M, Sola A, Rico M, Dominguez MD, Muruzabal J, Sanchez C. 652 poster MAGNETIC RESONANCE IMAGING-GUIDED BRACHYTHERAPY FOR CANCER OF CERVIX: CLINICAL RESULTS. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70774-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Manterola A, Asin G, Domínguez M, Arraras J, Sutmöller VC, Vila M, Mikel R. 760 poster IMPACT OF RADIOTHERAPY (RT) ON QUALITY OF LIFE (QL) IN ELDERLY WOMEN WITH BREAST CANCER. A PROSPECTIVE STUDY. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70882-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Arraras J, Arias F, Manterola A, Uzcanga M, Maravi E, Vila M, Chicata V, Eito C, Asin G, Zarandona U, Iturre EV, Dominguez MD. 185 oral QUALITY OF LIFE ASSESSMENT IN EARLY STAGES GLOTTIS CANCER PATIENTS WHO ARE IN THE FOLLOW-UP PERIOD. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70307-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
45
|
Couso I, Vila M, Rodriguez H, Vargas MA, León R. Overexpression of an exogenous phytoene synthase gene in the unicellular alga Chlamydomonas reinhardtii leads to an increase in the content of carotenoids. Biotechnol Prog 2011; 27:54-60. [DOI: 10.1002/btpr.527] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2010] [Revised: 09/06/2010] [Indexed: 11/06/2022]
|
46
|
Abstract
Fibreboard production is one of the most important industrial activities in Galicia (Spain). Great amounts of wastewater are generated, with properties depending on the type of wood, treatment process, final product and water reusing, among others. These effluents are characterized by a high chemical oxygen demand, low pH and nutrients limitation. Although anaerobic digestion is one of the most suitable processes for the treatment, lately bioplastics production (mainly polyhydroxyalkanoates) from wastewaters with mixed cultures is being evaluated. Substrate requirements for these processes consist of high organic matter content and low nutrient concentration. Therefore, wood mill effluents could be a suitable feedstock. In this work, the possibility of producing bioplastics from to wood mill effluents is evaluated. First, wood mill effluent was converted to volatile fatty acids in an acidogenic reactor operated at two different hydraulic retention times of 1 and 1.5 d. The acidification percentage obtained was 37% and 42%, respectively. Then, aerobic batch assays were performed using fermented wood mill effluents obtained at different hydraulic retention times. Assays were developed using different cultures as inoculums. The maximum storage yield of 0.57 Cmmol/Cmmol was obtained when when the culture was enriched on a synthetic media.
Collapse
Affiliation(s)
- M Ben
- Laboratory of Chemical Engineering, Faculty of Sciences, University of A Coruña Rúa da Fraga, nº 10, A Coruña 15008, Spain
| | | | | | | | | | | |
Collapse
|
47
|
Pando M, Gómez-Carrillo M, Vignoles M, Rubio A, dos Ramos Farias M, Vila M, Rossi D, Ralón G, Marone R, Reynaga E, Sosa J, Torres O, Maestri M, Ávila M, Salomón H. Incidence of HIV type 1 infection, antiretroviral drug resistance, and molecular characterization in newly diagnosed individuals in Argentina: A Global Fund Project. AIDS Res Hum Retroviruses 2011; 27:17-23. [PMID: 20860532 DOI: 10.1089/aid.2010.0013] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
An HIV incidence estimation was performed among men who have sex with men (MSM), drug users (DUs), sex workers (SWs), and pregnant women (PW) from Argentina. Volunteers older than 18 years old without a previous HIV-positive diagnosis were included. HIV-positive samples were analyzed by the Serological Testing Algorithm for Recent HIV Seroconversion (STARHS) to estimate incidence. By partial RT-PCR and sequencing of the HIV pol gene, an HIV subtype and resistance profile were determined. A total of 12,192 volunteers were recruited from October 2006 to September 2008. A higher HIV prevalence was detected among trans SWs (33.9%, 38/112), male SWs (10.8%, 12/111), and MSM 10.4% (161/1549). HIV incidence estimates by STARHS was also higher on trans SWs (11.31 per 100 person-years), male SWs (6.06 per 100 person-years), and MSM (6.36 per 100 person-years). Antiretroviral primary resistant mutations were detected in 8.4% of the study group, with a higher frequency in female DUs (33.3%). Phylogenetic analysis showed that 124 (57.9%) samples were subtype B, 84 (39.3%) intersubtype BF recombinants, 5 (2.3%) subtype C, and 1 (0.5%) subtype F in the pol region. Subtype B was most commonly found in MSM and male SWs whereas the intersubtype BF recombinant was more prevalent in female DUs, female SWs, and PW. Given the high HIV prevalence and incidence found in most of these groups, monitoring the continuing spread of the HIV epidemic is essential for determining public health priorities, assessing the impact of interventions, and estimating current and future health care needs.
Collapse
Affiliation(s)
- M.A. Pando
- Centro Nacional de Referencia para el SIDA, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - M. Gómez-Carrillo
- Centro Nacional de Referencia para el SIDA, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - M. Vignoles
- Centro Nacional de Referencia para el SIDA, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - A.E. Rubio
- Centro Nacional de Referencia para el SIDA, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - M.S. dos Ramos Farias
- Centro Nacional de Referencia para el SIDA, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - M. Vila
- Intercambios Asociación Civil, Buenos Aires, Argentina
| | - D. Rossi
- Intercambios Asociación Civil, Buenos Aires, Argentina
| | - G. Ralón
- Intercambios Asociación Civil, Buenos Aires, Argentina
| | - R. Marone
- Nexo Asociación Civil, Buenos Aires, Argentina
| | - E. Reynaga
- AMMAR, Asociación de Mujeres Meretrices de Argentina, Buenos Aires, Argentina
| | - J. Sosa
- AMMAR, Asociación de Mujeres Meretrices de Argentina, Buenos Aires, Argentina
| | - O. Torres
- Hospital Materno Infantil Ramón Sardá, Buenos Aires, Argentina
| | - M. Maestri
- Hospital Materno Infantil Ramón Sardá, Buenos Aires, Argentina
| | - M.M. Ávila
- Centro Nacional de Referencia para el SIDA, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - H. Salomón
- Centro Nacional de Referencia para el SIDA, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
48
|
Andreu J, Manzano-Piedras E, Bartomeus I, Dana ED, Vila M. Vegetation Response after Removal of the Invasive Carpobrotus Hybrid Complex in Andalucia, Spain. ECOL RESTOR 2010. [DOI: 10.3368/er.28.4.440] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
49
|
Lázaro L, Font E, Moreno E, Calvo R, Vila M, Andrés-Perpiñá S, Canalda G, Martínez E, Castro-Fornieles J. Effectiveness of self-esteem and social skills group therapy in adolescent eating disorder patients attending a day hospital treatment programme. Eur Eat Disord Rev 2010; 19:398-406. [PMID: 24081715 DOI: 10.1002/erv.1054] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE To evaluate self-esteem and social skills in adolescent eating disorder patients before and after specific group therapy as part of a Day Hospital Programme. METHOD One hundred and sixty adolescent eating disorder patients, classified as anorexia nervosa and related disorders (AN-rd) (N = 116) or bulimia nervosa and related disorders (BN-rd) (N = 44) received structured group therapy for developing self-esteem and social skills. RESULTS BN-rd patients had poorer perceptions of some self-esteem and social skills variables. After group therapy, both groups presented significant improvements in their perceptions of physical appearance, their self-concept related to weight and shape and to others, happiness and satisfaction, social withdrawal and leadership. BN-rd patients presented more changes on many of the variables. DISCUSSION Specific self-esteem and social skills group therapy in patients with eating disorders can be useful in improving certain core features.
Collapse
Affiliation(s)
- L Lázaro
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clínic Universitari, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Silva MA, Gomes PS, Vila M, Lopes MA, Santos JD, Silva RF, Fernandes MH. New titanium and titanium/hydroxyapatite coatings on ultra-high-molecular-weight polyethylene—
in vitro
osteoblastic performance. Biomed Mater 2010; 5:35014. [DOI: 10.1088/1748-6041/5/3/035014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|